Introduction
Ovarian cancer is a common solid tumor in women and, as reported by the National Central Cancer Registry of China, there were ~521,000 new cases and ~225,000 deaths in 2015 (1) . The increasing trend in mortality rate of ovarian cancer may be due to disease recurrence, despite significant advances in early detection and therapy (2, 3) . To improve treatment efficacy and reduce recurrence, a better understanding of the etiology of ovarian cancer is urgently required.
MicroRNAs (miRNAs/miR) are a class of small non-coding RNAs that are widely involved in the occurrence of cancer (4) . They have emerged as useful biomarkers for early diagnosis and prognosis as these small molecules are stable in blood and highly tumor-specific (5) . A recent systematic review of observational studies investigated the prognostic significance of miR-148a in various cancers and reported a correlation between low miR-148a levels and poor overall survival in patients with cancer (6) . miR-148a has been found to be dysregulated in several cancers, including ovarian cancer (7) , breast cancer (8, 9) , colorectal cancer (10), gastrointestinal cancer (11) , prostate cancer (12) , hepatocellular carcinoma (13) , papillary thyroid carcinoma (14) and renal cancer (15) . In ovarian cancer, miR-148a is decreased in the plasma of patients compared with healthy controls and its expression level is positively associated with survival time (16) .
In vitro cellular experiments have demonstrated that miR-148a inhibits proliferation, migration and invasion of ovarian cancer cell lines SKOV-3, OVCAR, ES-2 and A2780 (7, 16, 17) .
At present, the genes targeted by miR-148a are not fully elucidated. Forkhead box protein O3 (FOXO3, also known as FKHRL1) is predicted to be a target of miR-148a. FOXO3 belongs to the O subfamily of FOX transcription factors (18) . The FOXO factors regulate activities of multiple signaling pathways and serve critical roles during cellular growth, survival and carcinogenesis (19) . Therefore, it was hypothesized that miR-148a may act as a tumor suppressor in ovarian cancer by regulating FOXO3 expression. In vitro and in vivo experiments were performed to test this hypothesis. The present study may provide novel evidence for the treatment of ovarian cancer. Transfection. All the transfections were done using Lipofectamine 2000 transfection reagent according to the manufacturer's instructions. OVCAR3 and SKOV3 cells were seeded in 6-well plates (~1x10 5 cells/well) and grown to 70% confluence. For each well, the cells were transfected with 100 pmol miR-148a mimic (sense, 5'-UCA GUG CAU GAC AGA ACU UGG-3' and antisense, 5'-AAG TTC UGU CAU GCA CUG AUU-3') or miR-148a inhibitor (5'-ACA AAG UUC UGU AGU GCA CUG A-3'). Scrambled miRNA was used as a negative control (sense, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and antisense, 5'-ACG UGA CAC GUU CGG AGA ATT-3'). The miR-148a mimic and scrambled negative control were designed as previously described (7). Cells were collected 48 h after transfection, and the transfection efficiency was determined by RT-qPCR.
Overexpression of miR-148a inhibits viability and invasion of ovarian cancer OVCAR3 cells by targeting FOXO3
Cell viability. For the cell viability assay, OVCAR3 and SKOV3 cells were transfected with miR-148a mimic, miR-148a inhibitor or scrambled control for 48 h. Cells (~1x10 5 ) in 200 µl media were added to 96-well plates. After 24, 48 and 72 h, the number of viable cells was measured using CCK-8 according to manufacturer's protocol. The cell density was measured at 450 nm on a Bio-Rad Benchmark microplate reader (Bio-Rad Laboratories, Inc.).
Transwell assay. Cellular invasive ability was measured using a Transwell assay. OVCAR3 and SKOV3 cells were transfected with miR-148a mimic, inhibitor or scrambled negative control for 48 h. Cells were then harvested, suspended in serum-free media and seeded in Matrigel-coated 24-well plates (EMD Millipore). For each sample, 2x10 4 cells suspended in 200 µl serum-free media were added in the upper chambers and DMEM with 10% FBS was added in the lower chambers. After incubation for 24 h, non-invasive cells were removed and cells on lower surface were stained with 0.1% crystal violet at room temperature for 20 min. A total of six random visual fields in each well were visualized under a light microscope for cell counting at x200 magnification.
Cell apoptosis. For the cell apoptosis assay, OVCAR3 and SKOV3 cells were transfected with miR-148a mimic, inhibitor or scrambled control for 48 h. Cells were then harvested, washed with cold PBS and stained at 4˚C with Annexin V-FITC and propidium iodide for 10 min. The apoptosis rate (10 5 cells/sample) was detected on CytoFlex flow cytometer (Beckman Coulter, Inc.). FlowJo software (version 7.0; FlowJo LLC) was used to analyze flow cytometry data.
Bioinformatics. The prediction of the 3'-UTR of FOXO3 as the binding target of miR-148a binding target was performed using TargetScan software (http://www.targetscan.org). TargetScan is an online bioinformatic tool that predicts the target genes of miRNAs. If the miRNA and gene has paired sequences at the 3'UTR region, the gene was then predicted as a target of the miRNA.
Dual-luciferase reporter assay. The direct targeting interaction between miR-148a and FOXO3 was detected by dual-luciferase reporter assay. The hsa-miR-148a seed sequence in the 3'-untranslated region (UTR) of FOXO3 mRNA was cloned into the pmirGLO vector (Promega Corporation). A mutated sequence was generated and cloned into the vector. The reporter plasmids [FOXO3-wild type (WT) and FOXO3-mutant (MT)] were constructed by Shanghai GenePharma Co., Ltd. OVCAR3 and SKOV3 cells (1x10 5 cells/well) were co-transfected with pmirGLO reporter vector (600 ng) and a control Renilla luciferase vector pRL-CMV (400 ng; Promega Corporation) in the presence of the miR-148a mimic (50 ng/ml) or scrambled control. After incubation for 48 h, cells were harvested and the luciferase activities were detected using Dual-Luciferase Assay kit. Renilla luciferase activity was used as a reference for normalization Xenograft of nude mice. OVCAR3 cells were transfected with the miR-148a mimic or inhibitor for 48 h and harvested for the xenograft assay in nude mice. A total of 36 male C57BL/6 nude mice (weight, 22-24 g; age, 8 weeks; Shanghai SLAC Laboratory Animal Co., Ltd.) were randomly arranged into 3 groups (12/group). Mice were housed at 20-26˚C with 55±5% humidity, 12 h light/dark cycle and ad libitum access to food and water. Each mouse was injected with 5x10 6 cells (suspended in 100 µl PBS) in the lower back subcutaneously. At week 1, 2, 3 and 4 after inoculation, 3 mice were selected from each group and sacrificed to check tumor formation. Mice were sacrificed by intraperitoneal injection of sodium pentobarbital (150-200 mg/kg) Tumor volumes and weight were measured. The tumor volume was calculated with the formula 0.5x length x width 2 . Animal health and behavior were monitored every day. None of the animals presented with more than one tumor. The animal experimental protocol was reviewed and approved by the Animal Care and Use Committee of Jiangsu Taizhou People's Hospital.
RT-qPCR. Total RNA was extracted from tissue samples and cells using RNAiso Plus kit. First-strand cDNA was synthesized with PrimeScript 1st strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd.) at 37˚C for 15 min followed by 85˚C for 5 sec. The expression of miR-148a was quantified by qPCR in 20 µl reactions using SYBR Green PCR Master mix. The PCR reactions were carried out on Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific, Inc.). The PCR conditions were set as: 95˚C for 5 min; 40 cycles of 95˚C for 15 sec, 60˚C for 1 min and 72˚C for 30 sec. The primers used for qPCR were as follows: miR-148a forward, 5'-TCA GTG CAC TAC AGA ACT TTG T-3' and reverse, 5'-GCT GTC AAC GAT ACG CTA CGT-3'; and U6 forward, 5'-CTC GCT TCG GCA GCA CA-3' and reverse, 5'-AAC GCT TCA CGA ATT TGC GT-3'. The relative expression of miR-148a was normalized to the expression of U6 using the 2 -ΔΔCq method (22) .
Western blotting. Total protein extracts were prepared by lysing tissue and cells in RIPA lysis buffer (Beyotime Institute of Biotechnology). Protein concentrations were determined by bicinchoninic acid protein assay. Equal amounts of proteins (50 µg) were subjected to SDS-PAGE separation on 10% gels, transferred to polyvinylidene difluoride membranes (Merck KGaA) and blocked with 5% skim milk at room temperature for 4 h. Membranes were probed with primary antibodies overnight at 4˚C. The primary antibodies were used at 1:1,000 dilutions as follows: Rabbit monoclonal anti-FOXO3A (cat. no. ab109629), rabbit polyclonal anti-active caspase3 (cat. no. ab2302), rabbit monoclonal anti-pro-Caspase 3 (cat. no. ab32150) and rabbit polyclonal anti-GAPDH (cat. no. ab9485). GAPDH was used as an internal control. The membranes were then probed with goat anti-rabbit IgG (1:2,000; horseradish peroxidase-conjugated; cat. no. ab205718) at room temperature for 1 h. The chemiluminescence signals were detected by the ECL method. The relative protein expression levels were analyzed with Image-Pro Plus 6.0 software (Media Cybernetics Inc.).
Statistical analysis.
The statistical analysis was performed using SPSS 19.0 software (IBM Corp). Continuous variables were expressed as the mean ± standard deviation. At least three independent experiments were carried out for each assay. The differences between multiple groups was determined using one-way ANOVA with Fisher's Least Significant Difference test. Student's t-test was used to compare the difference between two groups. The clinical information in Table I was analyzed by χ   2 test. Pearson's correlation analysis was used to analysis the correlation between miR-148a and FOXO3 gene expression. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-148a is negatively associated with ovarian cancer viability. miR-148a expression was assessed in 20 human
ovarian cancer and adjacent normal tissues. As presented in Fig. 1A , the expression level of miR-148a in the cancer tissues decreased significantly compared with that in the adjacent normal tissues (P<0.01). Furthermore, the expression of miR-148a was monitored in ovarian cancer cell lines OVCAR3 and SKOV3, and normal human ovarian surface epithelial cell line HOSEpiC, and it was observed that the expression level of miR-148a was significantly downregulated in OVCAR3 and SKOV3 cells compared with HOSEpiC cells (Fig. 1B; P<0 .01). Subsequently, OVCAR3 and SKOV3 cells were transfected with miR-148a mimic, inhibitor or scrambled control and the transfection efficiency is presented in Fig. 1C .
The results of the CCK-8 assay revealed that cell viability was inhibited when miR-148a was overexpressed, while the miR-148a inhibitor promoted cell viability (Fig. 1D) . These results suggested that miR-148a expression may be associated with reduced ovarian cancer cell growth.
miR-148a inhibits cell invasion and promotes cell apoptosis in vitro.
To further investigate the anti-tumor role of miR-148a, the effects of miR-148a overexpression on cell invasion and apoptosis were determined. Transwell invasion assays showed that transfection with the miR-148a mimic suppressed the invasive ability of OVCAR3 cells to 68.8% of that of the scrambled control, but miR-148a mimic had no significant effect on the invasion of SKOV3 cells. miR-148a knockdown led to increased invasion ( Fig. 2A and B; P<0.01 ). In addition, miR-148a overexpression was found to promote apoptosis of OVCAR3 and SKOV3 cells. Cells transfected with miR-148a mimic had an apoptosis rate markedly higher than the scrambled control ( Fig. 2C and D; P<0 .01). The apoptosis rate was lower in cells transfected with the miR-148a inhibitor, but no significant differences were observed. The results indicated that miR-148a may act as a tumor suppressor for ovarian cancer by inhibiting cell invasion and promoting cell apoptosis. miR-148a directly targets FOXO3. The TargetScan database predicted FOXO3 as a direct target of miR-148a (Fig. 3A) . Based on the prediction results, miR-148a has three binding sites on the 3'UTR of FOXO3 which are 1007-1013, 2087-2093 and 2262-2268. Therefore, a dual-luciferase assay was performed to verify that miR-148a targets FOXO3 3'-UTR. The FOXO3-WT or FOXO3-MT was co-transfected with the miR-148a mimic into OVCAR3 cells. The luciferase activity significantly decreased in cells co-transfected with FOXO3-WT and miR-148a mimic ( Fig. 3B; P<0.01 ), but not in cells co-transfected with the mutant FOXO3-3'UTR sequence and miR-148a mimic. Furthermore, in the ovarian cancer tissues, the level of FOXO3 gene expression was negatively correlated with the expression of miR-148a (Fig. 3C) . Moreover, western blotting revealed that the FOXO3 protein level was downregulated by transfection with miR-148a mimic and upregulated by transfection with miR-148a inhibitor ( Fig. 3D and E) . The effect of the miR-148a level on cleaved caspase-3, a cell death protease, was also investigated. As shown in Fig. 3F and G, miR-148a inhibitor decreased the expression of cleaved caspase-3 and miR-148a overexpression increased the expression of cleaved caspase-3, which may explain the pro-apoptotic role of miR-148a.
miR-148a suppresses tumor growth in nude mice. The role of miR-148a in regulating ovarian cancer growth was further studied by tumor xenograft assay. Nude mice were injected with OVCAR3 cells transfected with miR-148a mimic or inhibitor. Both the tumor size and weight were smaller in the mice injected with cells overexpressing miR-148a compared with the mice injected with normal OVCAR3 cells. Tumors derived from cells with miR-148a knockdown exhibited increased tumor growth in nude mice compared with control animals (Fig. 4) . The results indicated that miR-148a may suppress tumor growth in vivo.
Discussion miRNAs are regulators of many oncobiological processes. In the present study, miR-148a overexpression inhibited cell viability, suppressed invasion and promoted apoptosis of OVCAR3 and SKOV3 cells. miR-148a also inhibited tumor growth in vivo. The regulatory role of miR-148a may be mediated by the FOXO3 transcription factor. miR-148a was reported to be downregulated in plasma samples of ovarian cancer patients (16) . miR-148a was also discovered to be decreased in ovarian cancer tissues of 65% of patients compared with the adjacent tissue, but the difference in expression was not significant (7) . Other studies also demonstrated that miR-148a is significantly downregulated in ovarian tissues compared with adjacent normal tissues (23, 24) , which is consistent with the results of the present study. Similarly, previous studies demonstrated that miR-148a regulates growth and apoptosis of ovarian cancer cells in vitro (23, 25) . In addition, the present study further illustrated that miR-148a reduced ovarian tumorigenesis in vivo.
Previous studies have identified several targets of miR-148a. Sphingosine-1-phosphate receptor 1 is a confirmed target of miR-148a in ovarian cancer SKOV3 cells (17) . miR-148a also promotes apoptosis of OVCAR8 cells by targeting Erbb3 and MYB (26) . miR-148a inhibits gastric cancer cell proliferation and invasion via inhibition of transforming growth factor-β-induced 2 (24). miR-148a was shown to promote paclitaxel-induced apoptosis of SKOV3 cells via direct inhibition of protein disulfide isomerase family A member 3, indicating that miR-148a is associated with chemotherapy efficacy (23) . FOXO3 was predicted as a target of miR-148a in the current study; however, it remains unclear whether miR-148a exerts its antitumor function in ovarian cancer cells via regulation of expression of FOXO3.
In the present study, the association between miR-148a and FOXO3 in ovarian cancer was explored. It was determined that the expression of miR-148a and FOXO3 mRNA were negatively correlated in ovarian cancer tissues and it was demonstrated that miR-148a inhibited FOXO3 expression in vitro. It is noteworthy that FOXO3 must translocate to the nucleus to initiate expression of tumor suppressing genes (27) . IκB kinase (IKK) expression or phosphorylated Akt could induce nuclear exclusion of FOXO3 and contributed to cancer cell proliferation (28) . Phosphorylation of Akt (29) and activation of IKK are commonly observed in ovarian cancer (30) . This additional regulatory mechanism of FOXO3 may override the upregulation by miR-148a. Similar results were observed by Liu et al (31) . That study reported that miR-498 was markedly downregulated in ovarian cancer cells and FOXO3 was a direct target of miR-498 (31) . These findings suggested that the mechanisms by which FOXO3 affects tumorigenesis are complex.
The present study has limitations. First, the number of the clinical samples included in the present study was relatively small and results should be verified using a larger sample size. Second, miR-148a has three binding sites on the 3'UTR of FOXO3 which are 1007-1013, 2087-2093 and 2262-2268, as predicted by Targetscan. In the present study, only the 1007-1013 site was verified and therefore, the other two sites should be verified in future studies.
In conclusion, the present study indicated that miR-148a may act as a tumor suppressor in ovarian cancer OVCAR3 and SKOV3 cells. The suppressive effect may be due to inhibiting cell viability and invasion as well as promoting apoptosis. FOXO3 was described as a target of miR-148a and mediated the anti-tumor role. Nevertheless, further study is required to understand the complex regulatory network of miR-148a.
